HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Clinicians call for reforms to slow ‘unsustainable’ rise in drug costs
• Availability of care for adults with sickle cell disease
• Tumor p16 status may predict response to panitumumab 
plus chemotherapy in metastatic SCCHN
• Report: Challenges persist in altering behaviors that increase cancer risk
• FDA approves lenalidomide for treatment of mantle cell lymphoma
• Breast cancer survivors not meeting minimum exercise recommendations
• Black men less likely to receive follow-up care after positive prostate exam
• Post-transplant infections successfully treated with virus-specific T cells
• Age, sex predict advanced neoplasia in screening CT colonography
• Entinostat plus exemestane improved outcomes in advanced ER-positive breast cancer
• HCV treatment improves survival among anemic patients
• Imaging metrics predicted OS in NSCLC treated with stereotactic ablative radiotherapy
• Preoperative transfusion reduced perioperative complications in sickle cell disease
• Risk factors identified for locoregional recurrence in triple-negative breast cancer
• Routine surveillance imaging provided no survival benefit in HL
• Cetuximab plus FOLFIRI extended survival in metastatic colorectal cancer
• Gene mutations common in black women at high risk for breast cancer
• GM-CSF plus ipilimumab extended OS in metastatic melanoma
• Idelalisib plus rituximab shows promise as frontline therapy for CLL
• New test improved prostate cancer risk assessment
• PTEN loss, PIK3CA mutation predicted resistance to cetuximab in HNSCC
• Vinegar screening technique reduced cervical cancer mortality by 31% in India
• Extended tamoxifen reduced breast cancer recurrence, mortality